Scientists from Singapore have demonstrated the critical role played by a special transporter protein in regulating the brain cells that ensure nerves are protected by coverings called myelin sheaths.
The findings, reported by researchers at Duke-NUS Medical School and the National University of Singapore in the Journal of Clinical Investigation, could help to reduce the damaging impacts of aging on the brain.
An insulating membrane encasing nerves, myelin sheaths facilitate the quick and effective conduction of electrical signals throughout the body’s nervous system. When the myelin sheath gets damaged, nerves may lose their ability to function and cause neurological disorders. With ageing, myelin sheaths may naturally start to degenerate, which is often why the elderly lose their physical and mental abilities.
“Loss of myelin sheaths occurs during the normal aging process and in neurological diseases, such as multiple sclerosis and Alzheimer’s disease,” said Dr Sengottuvel Vetrivel, Senior Research Fellow with Duke-NUS’ Cardiovascular & Metabolic Disorders (CVMD) Program and lead investigator of the study. “Developing therapies to improve myelination — the formation of the myelin sheath — in aging and disease is of great importance to ease any difficulties caused by declining myelination.”
To pave the way for developing such therapies, the researchers sought to understand the role of Mfsd2a, a protein that transports lysophosphatidylcholine (LPC) — a lipid that contains an omega-3 fatty acid — into the brain as part of the myelination process.
From what is known, genetic defects in the Mfsd2a gene leads to significantly reduced myelination and a birth defect called microcephaly, which causes the baby’s head to be much smaller than it should be.
In preclinical models, the team showed that removing Mfsd2a from precursor cells that mature into myelin-producing cells — known as oligodendrocytes — in the brain led to deficient myelination after birth.
Further investigations, including single-cell RNA sequencing, demonstrated that Mfsd2a’s absence caused the pool of fatty acid molecules — particularly omega-3 fats — to be reduced in the precursor cells, preventing these cells from maturing into oligodendrocytes that produce myelin.
“Our study indicates that LPC omega-3 lipids act as factors within the brain to direct oligodendrocyte development, a process that is critical for brain myelination,” explained Professor David Silver, the senior author of the study and Deputy Director of the CVMD Programme. “This opens up potential avenues to develop therapies and dietary supplements based on LPC omega-3 lipids that might help retain myelin in the aging brain — and possibly to treat patients with neurological disorders stemming from reduced myelination.”
Vetrivel Sengottuvel, Monalisa Hota, Jeongah Oh, Dwight L. Galam, Bernice H. Wong, Markus R. Wenk, Sujoy Ghosh, Federico Torta, David L. Silver. Deficiency in the omega-3 lysolipid transporter Mfsd2a leads to aberrant oligodendrocyte lineage development and hypomyelination. Journal of Clinical Investigation, 2023; DOI: 10.1172/JCI164118
Duke-NUS Medical School. (2023, May 5). A special omega-3 fatty acid lipid will change how we look at the developing and aging brain. ScienceDaily. Retrieved May 5, 2023 from www.sciencedaily.com/releases/2023/05/230505101659.htm
Photo by ready made from Pexels: https://www.pexels.com/photo/white-and-green-medication-pills-on-gray-surface-3850763/